{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-317784","form_type":"8-K","ticker":"ARTV","cik":"0001817241","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2025-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.573717+00:00","generated_at":"2026-05-16T13:22:49.949212+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Artiva Biotherapeutics exchanges underwater options for RSUs for CEO and COO","bullets":["CEO Fred Aslan surrendered 869,136 options (566,470 vested, 302,666 unvested) for equivalent RSUs with new vesting.","COO Jennifer Bush surrendered 84,877 options (60,372 vested, 24,506 unvested) for equivalent RSUs.","RSUs vest between Aug 2026 and Feb 2029; acceleration on termination without cause or resignation for good reason.","Purpose: retain employees and align interests with stockholders by replacing underwater options with current-value equity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-317784","json":"https://secwatch.observer/filing/0001193125-25-317784.json","markdown":"https://secwatch.observer/filing/0001193125-25-317784.md","text":"https://secwatch.observer/filing/0001193125-25-317784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525317784/0001193125-25-317784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525317784/artv-20251210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:22:49.949212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}